---
title: "Avience Biomedicals Ltd (AVIENCE) — Share Price, Financials & Analysis"
symbol: "AVIENCE"
company: "Avience Biomedicals Ltd"
canonical: "https://tapetide.com/stocks/AVIENCE"
isin: "INE0V9I01017"
nse_symbol: "AVIENCE"
sector: "Healthcare"
industry: "Healthcare Equipment & Supplies"
market_cap_cr: 182.93
generated_at: "2026-09-13T18:19:18.638Z"
---

# Avience Biomedicals Ltd (AVIENCE)

Canonical page: https://tapetide.com/stocks/AVIENCE

## Company

- **NSE Symbol:** AVIENCE
- **ISIN:** INE0V9I01017
- **Sector:** Healthcare
- **Industry:** Healthcare Equipment & Supplies
- **Macro Sector:** Healthcare
- **Stock Type:** EQUITY
- **Listed Since:** 2026-06-25
- **Face Value:** ₹10
- **F&O Eligible:** No
- **Website:** avienbio.com

## About

Incorporated in June 2024, Avience Biomedicals Limited is an ISO certified company specializing in manufacturing, supplying, and exporting molecular diagnostic solutions.[1]

## Latest Price

- **Price:** ₹385.35
- **Change:** +38.55 (+11.12%)
- **Open:** ₹356.1
- **Day High:** ₹388
- **Day Low:** ₹322
- **Previous Close:** ₹346.8
- **Volume:** 100200
- **As Of:** 2026-09-11T10:01:44+00:00

## Key Fundamentals

Observed at 2026-09-11T04:48:46.233414Z.

- **Market Cap:** ₹182.93 Cr
- **Classification:** SME
- **P/E (reported):** 21.7
- **Book Value:** ₹164.88
- **Price to Book:** 2.1
- **Dividend Yield:** 0%
- **ROE:** 31.33%
- **ROCE:** 34%
- **Debt to Equity:** 0.92
- **Revenue (yearly):** ₹41.84 Cr
- **Net Income:** ₹5.73 Cr
- **EBITDA:** ₹10.34 Cr
- **52-Week High:** ₹414.95
- **52-Week Low:** ₹208
- **RSI (14):** 76.52

## Key Insights

### Strengths

- Company has a good return on equity (ROE) track record: 3 Years ROE 37.9%

### Weaknesses

- Company might be capitalizing the interest cost

## Growth Rates

| Metric | 1Y | 3Y | 5Y |
| --- | --- | --- | --- |
| cash flow growth | 232.35% | -46.95% | 27.44% |
| ebitda margin growth | -6.81% | 31.82% | — |
| net income growth | -19.3% | 160.45% | — |
| revenue growth | -8.85% | 19.69% | — |
| roce | 19.47% | 19.47% | — |
| roe | -9.63% | 33% | — |

## Financial Statements

### Quarterly Results

All figures in ₹ crore unless the row name says otherwise.

| Item | Mar 2025 | Sep 2025 | Mar 2026 |
| --- | --- | --- | --- |
| Sales | 24.47 | 26.82 | 25.69 |
| Expenses | 17.86 | 19.57 | 18 |
| Operating Profit | 6.61 | 7.25 | 7.69 |
| OPM % | 27.01 | 27.03 | 29.93 |
| Other Income | 0.46 | 0.06 | 0.23 |
| Interest | 0.69 | 0.65 | 0.89 |
| Depreciation | 0.48 | 0.56 | 0.66 |
| Profit before tax | 5.9 | 6.1 | 6.37 |
| Tax % | 27.63 | 25.74 | 33.75 |
| Net Profit | 4.27 | 4.54 | 4.22 |
| EPS in Rs | 10.59 | 11.26 | 10.47 |

### Profit & Loss

All figures in ₹ crore unless the row name says otherwise.

| Item | Mar 2024 | Mar 2025 | Mar 2026 |
| --- | --- | --- | --- |
| Sales | 23.83 | 44.92 | 52.51 |
| Expenses | 19.65 | 33.4 | 37.57 |
| Operating Profit | 4.18 | 11.52 | 14.94 |
| OPM % | 17.54 | 25.65 | 28.45 |
| Other Income | 0.41 | 0.58 | 0.29 |
| Interest | 0.94 | 1.45 | 1.54 |
| Depreciation | 0.62 | 0.88 | 1.22 |
| Profit before tax | 3.03 | 9.77 | 12.47 |
| Tax % | 28.71 | 27.33 | 29.75 |
| Net Profit | 2.16 | 7.1 | 8.75 |
| EPS in Rs | 6.58 | 17.61 | 21.71 |
| Dividend Payout % | 0 | 0 | 0 |

### Balance Sheet

All figures in ₹ crore unless the row name says otherwise.

| Item | Mar 2024 | Mar 2025 | Mar 2026 |
| --- | --- | --- | --- |
| Equity Capital | 3.28 | 4.03 | 4.03 |
| Reserves | 2.94 | 18.63 | 27.38 |
| Borrowings | 15.13 | 22.16 | 28.94 |
| Other Liabilities | 13.18 | 11.6 | 17.59 |
| Total Liabilities | 34.53 | 56.42 | 77.94 |
| Fixed Assets | 10.25 | 13.1 | 16.06 |
| CWIP | 0.03 | 4.62 | 12.85 |
| Investments | 0.03 | 0.03 | 0.03 |
| Other Assets | 24.22 | 38.67 | 49 |
| Total Assets | 34.53 | 56.42 | 77.94 |

### Cash Flow

All figures in ₹ crore unless the row name says otherwise.

| Item | Mar 2024 | Mar 2025 | Mar 2026 |
| --- | --- | --- | --- |
| Cash from Operating Activity | 1.02 | 3.39 | 2.78 |
| Cash from Investing Activity | -3.9 | -9.55 | -9.04 |
| Cash from Financing Activity | 2.93 | 10.21 | 3.07 |
| Net Cash Flow | 0.05 | 4.05 | -3.19 |
| Free Cash Flow | -2.81 | -5.88 | -6.43 |
| CFO/OP | 29 | 36 | 35 |

### Ratios

| Item | Mar 2024 | Mar 2025 | Mar 2026 |
| --- | --- | --- | --- |
| Debtor Days | 123.91 | 139.84 | 146.11 |
| Inventory Days | 290.31 | 176.3 | 217.51 |
| Days Payable | 129.94 | 98.06 | 119.89 |
| Cash Conversion Cycle | 284.29 | 218.07 | 243.72 |
| Working Capital Days | 28.64 | 70.29 | 74.03 |
| ROCE % | — | 34.18 | 26.64 |

## Shareholding Pattern

### Quarterly

| Category | Dec 2024 | Jun 2026 |
| --- | --- | --- |
| Promoters | 92.85% | 64.59% |
| FIIs | 0% | 3.06% |
| DIIs | 0% | 9.08% |
| Government | 0% | 0% |
| Public | 0% | 13.57% |
| Others | 7.15% | 9.69% |
| No. of Shareholders | 33 | 38 |

## Filings & Documents

### Other Documents

| Date | Document |
| --- | --- |
| 9 Sep - Newspaper ads confirm annual report dispatch; 7th AGM on September 30, 2026 via VC/OAVM. | [Copy of Newspaper Publication 9 Sep - Newspaper ads confirm annual report dispatch; 7th AGM on September 30, 2026 via VC/OAVM.](https://nsearchives.nseindia.com/corporate/AVIENBIO_09092026103925_Post_dispatch_AGM_Notice_Advertisment_Avience.pdf) |
| 8 Sep - Notice of 7th AGM on 30 Sep 2026; seeks auditor changes and borrowing powers up to Rs100 crore. | [Updates 8 Sep - Notice of 7th AGM on 30 Sep 2026; seeks auditor changes and borrowing powers up to Rs100 crore.](https://nsearchives.nseindia.com/corporate/AVIENBIO_08092026111653_Intimation_of_AGM_Annual_Report.pdf) |
| 8 Sep - Newspaper publication shared for Avience Biomedicals’ 7th AGM on September 30, 2026 at 11:30 A.M. | [Copy of Newspaper Publication 8 Sep - Newspaper publication shared for Avience Biomedicals’ 7th AGM on September 30, 2026 at 11:30 A.M.](https://nsearchives.nseindia.com/corporate/AVIENBIO_08092026074618_Pre-dispatch_Intimation_Avience.pdf) |
| 8 Sep - AGM notice and annual report web links shared with shareholders. | [Updates 8 Sep - AGM notice and annual report web links shared with shareholders.](https://nsearchives.nseindia.com/corporate/AVIENBIO_08092026232208_Letter_to_Shareholders_Avience.pdf) |
| 8 Sep - 7th AGM on 30 Sep 2026; adopts FY26 accounts, auditor appointments, and borrowing powers up to Rs100 crore. | [Shareholders meeting 8 Sep - 7th AGM on 30 Sep 2026; adopts FY26 accounts, auditor appointments, and borrowing powers up to Rs100 crore.](https://nsearchives.nseindia.com/corporate/AVIENBIO_08092026121411_Notice_of_Shareholder_Meeting_Annual_Report.pdf) |
| 7 Sep - Board approved 7th AGM on 30 Sep 2026, auditor changes, and borrowing-power agenda. | [Outcome of Board Meeting 7 Sep - Board approved 7th AGM on 30 Sep 2026, auditor changes, and borrowing-power agenda.](https://nsearchives.nseindia.com/corporate/AVIENBIO_07092026184854_BOARD_MEETING_OUTCOME_AVIENCE_07-09-2026.pdf) |
| 29 Jul - Submitted Regulation 74(5) certificate for quarter ended June 30, 2026. | [Certificate under SEBI (Depositories and Participants) Regulations, 2018 29 Jul - Submitted Regulation 74(5) certificate for quarter ended June 30, 2026.](https://nsearchives.nseindia.com/corporate/AVIENBIO_29072026201844_Certificate_Regulation_74_5__Sebi_DP__Signed.pdf) |
| 29 Jul - Filed reconciliation of share capital audit certificate for quarter ended June 30, 2026; no changes reported. | [Certificate under SEBI (Depositories and Participants) Regulations, 2018 29 Jul - Filed reconciliation of share capital audit certificate for quarter ended June 30, 2026; no changes reported.](https://nsearchives.nseindia.com/corporate/AVIENBIO_29072026204041_Reconciliation_of_Share_Capital_Audit_Certificate.pdf) |
| 29 Jul - Avience Biomedicals says corporate governance provisions are not applicable for quarter ended June 30, 2026. | [Quarterly Compliance Report on Corporate governance - within 21 days from the end of the quarter 29 Jul - Avience Biomedicals says corporate governance provisions are not applicable for quarter ended June 30, 2026.](https://nsearchives.nseindia.com/corporate/AVIENBIO_29072026202927_Non-applicability_of_compliance_related_to_Corporate_Governance.pdf) |
| 28 Jul - Avience Biomedicals filed H2/FY26 earnings call transcript; FY26 revenue rose to ₹52.51 crore, PAT to ₹8.75 crore. | [Analysts/Institutional Investor Meet/Con. Call Updates 28 Jul - Avience Biomedicals filed H2/FY26 earnings call transcript; FY26 revenue rose to ₹52.51 crore, PAT to ₹8.75 crore.](https://nsearchives.nseindia.com/corporate/AVIENBIO_28072026233742_Transcript_H2_FY26_Concall__Avience.pdf) |

### Annual Reports

| Date | Document |
| --- | --- |
| from nse | [Annual Report 2026 from nse](https://archives.nseindia.com/annual_reports/SME_AR_31840_AVIENCE_2025_2026_A_3985054_08092026113304.pdf) |

---

Provenance differs by section. Financial statements, shareholding and filings are as reported in company disclosures to NSE/BSE/SEBI. Price, volume and 52-week levels are exchange market data. Technical indicators are computed by Tapetide from daily closing prices. The Tapetide Score is Tapetide's own analysis. Analyst ratings are third-party estimates, not company statements. All figures are for research and information only and are not investment advice. Generated 2026-09-13T18:19:18.638Z.